癌症生物標記市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球癌症生物標記市場價值為 275 億美元，預計 2025 年至 2034 年期間的複合年成長率為 12.4%。癌症生物標記包括血液、組織和體液中的蛋白質、基因和各種分子，正成為現代腫瘤學的重要工具。隨著全球癌症盛行率持續飆升，這些生物標記正在徹底改變醫療保健專業人員檢測、監測和治療不同形式癌症的方式。它們在早期診斷癌症、評估病情進展和製定個人化治療方案方面發揮關鍵作用，最終提高了患者的生存率和生活品質。隨著醫療保健系統努力提高診斷準確性，同時減少不必要的治療，對精準醫療和標靶治療的日益重視進一步推動了對先進生物標記技術的需求。

分子診斷領域的持續研究和創新也擴大了生物標記的範圍，使其在臨床試驗、藥物開發和治療監測中變得不可或缺。癌症是全球主要死亡原因之一，將生物標記整合到常規臨床實踐中正在獲得發展勢頭，因為它們在症狀出現之前就能夠識別癌症，從而實現早期干預並獲得更好的結果。此外，液體活體組織切片、基因組分析和蛋白質組學的不斷改進正在拓寬癌症生物標記的潛在應用，為非侵入性和高度準確的癌症檢測解決方案提供新的途徑。

癌症生物標記檢測市場中的儀器部分在 2024 年創造了 117 億美元的收入，預計從 2025 年到 2034 年的複合年成長率將達到 12.3%。聚合酶鏈反應 (PCR) 機器、次世代定序 (NGS) 平台和質譜儀等先進診斷工具處於癌症生物標記研究的前沿。這些儀器在檢測與癌症相關的基因突變和分子特徵方面具有無與倫比的靈敏度和精確度。它們還支援連接複用，從而可以在單次測試中同時分析多個生物標記，顯著提高效率和成本效益。這些儀器中尖端技術的整合確保了更快的診斷、更高的可靠性和更廣泛的可及性，這使得它們對於不斷擴大的癌症生物標記領域至關重要。

市場根據癌症類型進行細分，包括乳癌、攝護腺癌、大腸癌、子宮頸癌、肝癌和肺癌。乳癌領域在 2024 年佔據主導地位，佔 28.6%，預計到 2034 年將達到 259 億美元。生物標記對於早期檢測乳癌至關重要，CA 15-3 和 CA 27-29 等測試與傳統影像方法結合使用時，是提高診斷精確度的重要工具。全球乳癌發生率的持續上升以及人們對早期篩檢方法的認知的提高是該領域成長的關鍵因素。

2023 年，美國癌症生物標記市場價值達 92 億美元，成為全球領先的區域市場之一。全國癌症發病率的飆升，加上基於生物標記的診斷解決方案的進步，正在推動市場強勁成長。對早期檢測和個人化醫療的需求不斷成長，使美國成為癌症生物標記研究和創新的重要中心。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 癌症發生率上升
    • 個人化醫療的進展
    • 診斷工具的技術進步
    • 增加研發活動
  • 產業陷阱與挑戰
    • 生物標記開發和測試成本高昂
    • 缺乏標準化
• 成長潛力分析
• 監管格局
• 技術格局
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按產品，2021 年至 2034 年

• 主要趨勢
• 儀器
• 耗材
• 軟體

第6章：市場估計與預測：按癌症類型，2021 年至 2034 年

• 主要趨勢
• 乳癌
• 攝護腺癌
• 大腸直腸癌
• 子宮頸癌
• 肝癌
• 肺癌
• 其他癌症類型

第7章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 藥物發現與開發
• 診斷
• 個人化醫療
• 其他應用

第8章：市場估計與預測：按技術，2021 年至 2034 年

• 主要趨勢
• 組學技術
  • 蛋白質體學
  • 基因組學
  • 其他 OMICS 技術
• 影像技術
  • 超音波
  • 電腦斷層掃描
  • 磁振造影
  • 正子斷層掃描
  • 乳房X光檢查

第9章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院
• 診斷實驗室
• 生物製藥公司
• 學術和研究機構
• 其他最終用途

第10章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：公司簡介

• Abbott Laboratories
• Agilent Technologies
• Bio-Rad Laboratories
• Becton, Dickinson and Company
• BioGenex
• Centogene
• F. Hoffmann-La Roche
• Hologic
• INOVIQ
• Illumina
• Merck & Co.
• QIAGEN
• Sino Biological
• Sysmex Corporation
• Thermo Fisher Scientific

The Global Cancer Biomarkers Market was valued at USD 27.5 billion in 2024 and is projected to grow at a CAGR of 12.4% between 2025 and 2034. Cancer biomarkers, which comprise proteins, genes, and various molecules found in blood, tissues, and bodily fluids, are becoming essential tools in modern oncology. As cancer prevalence continues to surge worldwide, these biomarkers are revolutionizing the way healthcare professionals detect, monitor, and treat different forms of cancer. They play a pivotal role in diagnosing cancer at an early stage, evaluating disease progression, and tailoring personalized therapies, ultimately enhancing patient survival rates and quality of life. The growing emphasis on precision medicine and targeted therapies is further driving demand for advanced biomarker technologies, as healthcare systems strive to improve diagnostic accuracy while reducing unnecessary treatments.

Ongoing research and innovation in molecular diagnostics are also expanding the scope of biomarkers, making them indispensable in clinical trials, drug development, and treatment monitoring. With cancer being one of the leading causes of death globally, the integration of biomarkers into routine clinical practice is gaining momentum, as they hold immense promise in identifying cancer even before symptoms arise, thereby enabling early interventions and better outcomes. Moreover, the continuous improvements in liquid biopsy, genomic analysis, and proteomics are broadening the potential applications of cancer biomarkers, offering new avenues for non-invasive and highly accurate cancer detection solutions.

The instruments segment in the cancer biomarker detection market generated USD 11.7 billion in 2024 and is anticipated to grow at a CAGR of 12.3% from 2025 to 2034. Advanced diagnostic tools such as polymerase chain reaction (PCR) machines, next-generation sequencing (NGS) platforms, and mass spectrometers are at the forefront of cancer biomarker research. These instruments offer unmatched sensitivity and precision in detecting genetic mutations and molecular signatures associated with cancer. They also support multiplexing, which allows simultaneous analysis of multiple biomarkers in a single test, significantly improving efficiency and cost-effectiveness. The integration of cutting-edge technologies in these instruments ensures faster diagnosis, enhanced reliability, and broader accessibility, making them critical to the expanding cancer biomarkers landscape.

The market is segmented based on cancer types, including breast, prostate, colorectal, cervical, liver, and lung cancers. The breast cancer segment accounted for a dominant share of 28.6% in 2024 and is forecasted to reach USD 25.9 billion by 2034. Biomarkers are fundamental in detecting breast cancer at an early stage, with tests like CA 15-3 and CA 27-29 serving as important tools to improve diagnostic precision when used alongside traditional imaging methods. The continuously rising incidence of breast cancer globally and increasing awareness about early screening methods are key contributors to the growth of this segment.

The U.S. Cancer Biomarkers Market generated USD 9.2 billion in 2023, positioning itself as one of the leading regional markets worldwide. The surging cancer rates across the country, combined with advancements in biomarker-based diagnostic solutions, are driving robust market growth. Increasing demand for early detection and personalized medicine continues to make the U.S. a significant hub for cancer biomarker research and innovation.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cancer
    • 3.2.1.2 Advancements in personalized medicine
    • 3.2.1.3 Technological advancements in diagnostic tools
    • 3.2.1.4 Increasing research and development activities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs of biomarker development and testing
    • 3.2.2.2 Lack of standardization
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Consumables
• 5.4 Software

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Breast cancer
• 6.3 Prostate cancer
• 6.4 Colorectal cancer
• 6.5 Cervical cancer
• 6.6 Liver cancer
• 6.7 Lung cancer
• 6.8 Other cancer types

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Drug discovery and development
• 7.3 Diagnostics
• 7.4 Personalized medicine
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Technology, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 OMICS technologies
  • 8.2.1 Proteomics
  • 8.2.2 Genomics
  • 8.2.3 Other OMICS technologies
• 8.3 Imaging technologies
  • 8.3.1 Ultrasound
  • 8.3.2 Computed tomography
  • 8.3.3 Magnetic resonance imaging
  • 8.3.4 Positron emission tomography
  • 8.3.5 Mammography

Chapter 9 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Diagnostic laboratories
• 9.4 Biopharmaceutical companies
• 9.5 Academic and research institutions
• 9.6 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 Agilent Technologies
• 11.3 Bio-Rad Laboratories
• 11.4 Becton, Dickinson and Company
• 11.5 BioGenex
• 11.6 Centogene
• 11.7 F. Hoffmann-La Roche
• 11.8 Hologic
• 11.9 INOVIQ
• 11.10 Illumina
• 11.11 Merck & Co.
• 11.12 QIAGEN
• 11.13 Sino Biological
• 11.14 Sysmex Corporation
• 11.15 Thermo Fisher Scientific